Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...

Patients with severe hypercholesterolemia who are unresponsive to a number of lipid-lowering therapies, including a PCSK9 inhibitor and high-dose statin, can have a significant reduction in ...

Pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) are produced in large quantities locally in the joints and subsequently enter the bloodstream. TNF-α and IL-6 may promote LDL metabolism by ...

When it comes to eating nuts for better cholesterol, a little goes a long way. Just a handful (1 ounce) of nuts a day, such ...

For people who have experienced a heart attack or stroke, or who are at high risk of one and need further cholesterol lowering, a new daily pill may be a more convenient yet similarly effective option ...